Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AnaptysBio, Inc.
This is a Phase 2, randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female aged 18 to 65 years and in good general health
Moderate to severe AD for at least 6 months prior to Randomization
History of inadequate response to treatment for AD with topical medications or for whom topical treatments are otherwise medically inadvisable
EASI score ≥ 16 at Screening and at Randomization
vIGA AD score ≥ 3 at Screening and at Randomization
AD involved BSA ≥ 10% at Screening and at Randomization
You may not be if
Any factors that in the Investigator's opinion would predispose the subject to develop an infection
Known or suspected congenital or acquired immunodeficiency state, or condition that would compromise the subject's immune status
Not able to tolerate SC drug administration
Tanning booth use or extended sun exposure that could affect disease severity or interfere with disease assessments within 4 weeks before Randomization
Clareo Health | This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).
